Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.45 |
| ▸ | CNR1 | P21554 | 9/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 2/20 | 0.39 |
| ▸ | GPR183 | P32249 | 2/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13566120 | 0.87 | CNR2 (0.40) | CNR2CNR1DRD3PDE2AGPR183 | |
| SCHEMBL18879812 | 0.81 | CNR2 (0.38) | CNR2CNR1DRD3PDE2AGPR183 | |
| SCHEMBL2662891 | 0.79 | PDE2A (0.43) | PDE2AGPR183CTNNB1WNT3A | |
| SCHEMBL14446464 | 0.77 | CNR2 (0.40) | CNR2CNR1DRD3PDE2A | |
| SCHEMBL18768656 | 0.76 | PDE2A (0.41) | PDE2AGPR183CTNNB1WNT3A | |
| SCHEMBL25923323 | 0.74 | GPR183 (0.32) | CNR2CNR1DRD3PDE2AGPR183 | |
| SCHEMBL16237855 | 0.74 | PDE2A (0.37) | CNR2PDE2AGPR183CTNNB1WNT3A | |
| SCHEMBL18649452 | 0.73 | DRD3 (0.42) | CNR2CNR1DRD3 | |
| SCHEMBL18649325 | 0.73 | HPGD (0.44) | CNR2CNR1DRD3CTNNB1 | |
| SCHEMBL16237862 | 0.73 | CTNNB1 (0.45) | PDE2AGPR183CTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-15 | — | — | US | disclosed |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | CNR2 3466/4885CNR1 2850/4885DRD3 3581/4885 |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | CNR2 3466/4885CNR1 2850/4885DRD3 3581/4885 |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | CNR2 528/4885CNR1 864/4885DRD3 4143/4885 |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | CNR2 528/4885CNR1 864/4885DRD3 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.